Aptevo Therapeutics Inc (APVO)
0.1793
0.00 (0.00%)
USD |
NASDAQ |
Sep 27, 16:00
0.179
0.00 (0.00%)
After-Hours: 20:00
Aptevo Therapeutics Research and Development Expense (Annual): 17.11M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.11M |
| December 31, 2022 | 17.88M |
| December 31, 2021 | 18.99M |
| December 31, 2020 | 17.85M |
| December 31, 2019 | 24.76M |
| December 31, 2018 | 35.38M |
| Date | Value |
|---|---|
| December 31, 2017 | 29.02M |
| December 31, 2016 | 29.12M |
| December 31, 2015 | 34.73M |
| December 31, 2014 | 46.59M |
| December 31, 2013 | 38.07M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.11M
Minimum
2023
24.76M
Maximum
2019
19.32M
Average
17.88M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Cassava Sciences Inc | 89.42M |
| Ocular Therapeutix Inc | 61.06M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 5.185M |